Related references
Note: Only part of the references are listed.Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary
J. Tanizaki et al.
ANNALS OF ONCOLOGY (2022)
Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better
Ming Zheng
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP
Gunnar Folprecht et al.
BRITISH JOURNAL OF CANCER (2021)
A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience
Chantal Pauli et al.
ONCOLOGIST (2021)
Comparative genomic characterization of melanoma of known and unknown primary
E. Rassy et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2021)
Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary
Elie Rassy et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2021)
Cancer of Unknown Primary in the Molecular Era
Shumei Kato et al.
TRENDS IN CANCER (2021)
Cancer of unknown primary: Incidence rates, risk factors and survival among adolescents and young adults
Nicholas Pavlidis et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Exploring the biological hallmarks of cancer of unknown primary: where do we stand today?
Elie Rassy et al.
BRITISH JOURNAL OF CANCER (2020)
New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?
Elie Rassy et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
The role of site-specific therapy for cancers of unknown of primary: A meta-analysis
Elie Rassy et al.
EUROPEAN JOURNAL OF CANCER (2020)
Long-term results of elective mucosal irradiation for head and neck cancer of unknown primary in Chinese population: The EMICUP study
Shengjin Dou et al.
CANCER MEDICINE (2020)
The diagnostic challenges of patients with carcinoma of unknown primary
Elie Rassy et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2020)
Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial
Hidetoshi Hayashi et al.
JAMA ONCOLOGY (2020)
A new entity of abdominal squamous cell carcinoma of unknown primary
Elie El Rassy et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2019)
Does Cancer of Unknown Primary (CUP) Truly Exist as a Distinct Cancer Entity?
Tilmann Bochtler et al.
FRONTIERS IN ONCOLOGY (2019)
Comprehensive management of HPV-related squamous cell carcinoma of the head and neck of unknown primary
Elie Rassy et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2019)
A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)
K. Fizazi et al.
ANNALS OF ONCOLOGY (2019)
Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site
Hidetoshi Hayashi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary
Simron Singh et al.
NEUROENDOCRINOLOGY (2018)
Treatment for retropharyngeal metastatic undifferentiated squamous cell carcinoma from an unknown primary site: results of a prospective study with irradiation to nasopharyngeal mucosa plus bilateral neck
Chengrun Du et al.
ONCOTARGET (2017)
Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance)
H. H. Yoon et al.
ANNALS OF ONCOLOGY (2016)
A phase II trial of modified FOLFOX6 as first-line therapy for adenocarcinoma of an unknown primary site
Dong-Yeop Shin et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site
Shinjiro Sakamoto et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Total Mucosal Irradiation with Intensity-modulated Radiotherapy in Patients with Head and Neck Carcinoma of Unknown Primary: A Pooled Analysis of Two Prospective Studies
T. M. Richards et al.
CLINICAL ONCOLOGY (2016)
Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis
Sebastian Moran et al.
LANCET ONCOLOGY (2016)
Age-Dependent Metastatic Spread and Survival: Cancer of Unknown Primary as a Model
Kari Hemminki et al.
SCIENTIFIC REPORTS (2016)
Paclitaxel/Carboplatin With or Without Belinostat as Empiric First-Line Treatment for Patients With Carcinoma of Unknown Primary Site: A Randomized, Phase 2 Trial
John D. Hainsworth et al.
CANCER (2015)
Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary
Sameh Mikhail et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Observed Advantages of the STAMPEDE Study Design
Howard I. Scher
EUROPEAN UROLOGY (2015)
Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute
John D. Hainsworth et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Mutational landscape and significance across 12 major cancer types
Cyriac Kandoth et al.
NATURE (2013)
Cancer of unknown primary site
Nicholas Pavlidis et al.
LANCET (2012)
Carcinoma of unknown primary (CUP)
Nicholas Pavlidis et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2009)
Share Paper
